Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Mirdametinib
Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics
Successful Treatment of Bowen's Disease with Topical Maxacalcitol
68)/b54-50+/t41-
and p38 despite the different patterns of activation in these cells
B-HT 920 - CAS# 36085-73-1 Size:Solid 10 mg MirdametinibTalipexole, also known as B HT920 and Domnin, is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre and post synaptic receptors. It also is an 2 adrenergic agonist. The main side effects are drowsiness, dizziness,
US$ 390.00
US$ 164.45
US$ 693.50
US$ 149.50
US$ 247.00
US$ 602.80
US$ 462.00
US$ 326.00
US$ 261.00
US$ 353.50